Author(s):
Savitha. A, Ankita Bist, Preeti Dharapur
Email(s):
ankitabist9@gmail.com
DOI:
10.52711/0974-360X.2025.00634
Address:
Savitha. A1, Ankita Bist2*, Preeti Dharapur3
1Assistant Professor, Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar - 585401, Karnataka.
2Associate Professor, Dept. of Pharmacology, Government Medical college, Haldwani - 263139, Uttarakhand India.
3Assistant Professor, Department of Pharmacology, Bidar Institute of Medical Sciences, Bidar - 585401, Karnataka.
*Corresponding Author
Published In:
Volume - 18,
Issue - 9,
Year - 2025
ABSTRACT:
Acyclovir, has been the predominant oral antiviral agent for the treatment of acute herpes zoster for past many years, especially in the government supply. Limited oral bioavailability of acyclovir requires frequent dosing, one of the reasons that makes it non-patient friendly. This study aimed to assess the efficacy, tolerability and adverse drug reactions of the other drugs valacyclovir and famciclovir used in treatment of Herpes Zoster and to compare their effectiveness with acyclovir, in preventing post herpetic neuralgia. 90 patients with herpes zoster presenting within 72hours of the onset of rash were enrolled and randomized into three groups of 30 each and were assigned acyclovir, valacyclovir and famciclovir respectively. The treatments were given for 7 days. Patients were periodically followed up till day 29 to assess the effect of the drugs. A statistically significant reduction of skin lesion and zoster associated pain were noticed in valacyclovir group day 22(P=0.013) and day 29(P=0.0004). A significantly greater proportion of patients in Valacyclovir group did not have Zoster associated pain at day 29(P=0.003). All the three drugs showed significant reduction in pain scores within the group between 2 consecutive visits. The reduction of pain was best with Valacyclovir followed by Famciclovir and least in Acyclovir. Other than resolution of pain which is faster with Valacyclovir compared to Acyclovir and Famciclovir, there is no difference in outcome of rash healing, abnormal sensation and adverse effect with three drugs. The results of the present study show that administration of Valacyclovir is a much more effective alternative in the treatment of Acute Herpes Zoster compared to acyclovir and famciclovir
Cite this article:
Savitha. A, Ankita Bist, Preeti Dharapur. Comparison of Efficacy, Tolerability and Adverse effect Profile of Acyclovir, Valacyclovir and Famciclovir in the Management of Herpes Zoster. Research Journal of Pharmacy and Technology. 2025;18(9):4420-4. doi: 10.52711/0974-360X.2025.00634
Cite(Electronic):
Savitha. A, Ankita Bist, Preeti Dharapur. Comparison of Efficacy, Tolerability and Adverse effect Profile of Acyclovir, Valacyclovir and Famciclovir in the Management of Herpes Zoster. Research Journal of Pharmacy and Technology. 2025;18(9):4420-4. doi: 10.52711/0974-360X.2025.00634 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-9-54
REFERENCES:
1. Parkar S, Kegade P, Gade A, Sawant R. A Review on - Herpes Zoster. Asian J. Res. Pharm. Sci. 2020; 10(4): 282-286.
2. Cui JZ, Zhang XB, Zhu P, Zhao ZB, Geng ZS, Zhang YH, et al. Effect of repetitive intracutaneous injections with local anesthetics and steroids for acute thoracic herpes zoster and incidence of postherpetic neuralgia. Pain Med. 2017; 18: 1566-72.
3. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: Towards a global perspective. BMJ Open. 2014; 4: e004833.
4. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995; 39: 1546-53.
5. Cui JZ, Zhang J, Yan F, Yang X, Wang XL, Zhao Z, et al. Effect of Single Intra-cutaneous Injection for Acute Thoracic Herpes Zoster and Incidence of Postherpetic Neuralgia. Pain Manag Nurs. 2018; 19(2): 186-194. doi: 10.1016/j.pmn.2017.09.002. Epub 2017 Nov 15. PMID: 29153295.
6. Jeon YH. Herpes zoster and postherpetic neuralgia: Practical consideration for prevention and treatment. Korean J Pain. 2015; 28: 177‑84.
7. Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for post-herpetic neuralgia in the UK. Pharmacoeconomics. 1994; 6: 142-8.
8. Parkar S, Kegade P, Gade A, Sawant R. An Overview of Herpes zoster: Aetiology, Pathogenesis and Treatment. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(2): 140-4..
9. Manglavat SK, Kumawat D, Goswami R. Process Validation for Antiviral Famciclovir tablet. Asian J. Pharm. Tech. 2020; 10(3): 170-178.
10. John AR, Canaday DH. Herpes zoster in the older adult. Infect Dis Clin North Am. 2017; 31: 811-26.
11. Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain. 2021; 34: 509-33.
12. Yaldiz M, Solak B, Kara RO, Cosansu N, Erdem MT. Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster. Am J Ther. 2018; 25: e626-34.
13. Lin WR, Lin HH, Lee SS, Tsai HC, Huang CK, Wann SR et al. Comparative study of the efficacy and safety of valacyclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect. 2001; 34: 138-42.
14. Achar A, Chakraborty PP, Ghosh T, Naskar B, Guharay T, Bisai S. Clinical efficacy and tolerability of valacyclovir versus acyclovir in treatment of herpes zoster. Iran J Dermatol. 2011; 14: 52-57.
15. James WD, Berger TG, Elston DM, editors. Andrews’ diseases of the skin clinical dermatology. Tenth edition. Philadelphia: Saunders Elsevier. 2006: 379-84.
16. Bist A, Savitha A, Gumma K M. Efficacy of valacyclovir and famciclovir in herpes zoster: A comparative study. Indian J Pharmacol. 2020; 52: 472-5. DOI: 0.4103/ijp.IJP_555_18.
17. Schuster AK, Harder BC, Schlichtenbrede FC, Jarczok MN, Tesarz J. Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients. Cochrane Database Syst Rev. 2016; 14; 11(11): CD011503. doi: 10.1002/14651858.CD011503.pub2. PMID: 27841441; PMCID: PMC6464932.
18. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster. Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000; 9(9): 863-9.
19. Pott Junior H., de Oliveira M.F.B., Gambero S., Amazonas R.B. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. International Journal of Infectious Diseases. 2018; 72: 11-15.
20. Kim SH. Current scenario and future applicability of antivirals against herpes zoster. Korean J Pain. 2023; 36: 4-10. https://doi.org/10.3344/kjp.22391
21. Singh D, Bharti D, Bhattacharya I, Devi. CS. Epidemiological Survey of Subjects in the age group of 18 to 24 Years for Failed Secondary Response to Varicella Zoster Virus (VZV). Research J. Pharm. and Tech. 2018; 11(7): 2817-2820.